Oxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector® platform. 2018 saw significant growth in gross income, primarily through licensing deals, to deliver OXB’s first underlying operating profit. OXB is, however, carrying a significant loan of $55m, which is relatively expensive with an interest rate of 9% plus US LIBOR, and
18 Jun 2019
De-leveraging the balance sheet
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
De-leveraging the balance sheet
Oxford BioMedica plc (OXB:LON) | 221 3.3 0.7% | Mkt Cap: 221.0m
- Published:
18 Jun 2019 -
Author:
Martin Hall -
Pages:
12
Oxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector® platform. 2018 saw significant growth in gross income, primarily through licensing deals, to deliver OXB’s first underlying operating profit. OXB is, however, carrying a significant loan of $55m, which is relatively expensive with an interest rate of 9% plus US LIBOR, and